Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Infinity Announces Presentations On IPI-549 At Upcoming American Society of Clinical Oncology Annual Meeting | ||
By: PR Newswire Association LLC. - 08 May 2018 | Back to overview list |
|
CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), announced today that data from the ongoing clinical trial of IPI-549 will be presented in three events on June 4th during the American Society of Clinical Oncology (ASCO) Annual Meeting. Investor Event 6:30 a.m. CT – 7:30 a.m. CT Poster Session 8:00 a.m. CT – 11:00 a.m. CT Poster Discussion Session 11:30 a.m. CT – 12:45 p.m. CT About IPI-549 and the Ongoing Phase 1/1b Study The ongoing Phase 1/1b study being conducted by Infinity is designed to evaluate the safety, tolerability, activity, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy and in combination with Opdivo® in approximately 200 patients with advanced solid tumors.[iii] The study includes monotherapy and combination dose-escalation components, in addition to monotherapy expansion and combination expansion components. The monotherapy dose-escalation and expansion components are complete. The combination dose-escalation component is also complete, and combination expansion cohorts are enrolling. The combination expansion component of the study includes multiple cohorts designed to evaluate IPI-549 in patients with specific types of cancer, including patients with non-small cell lung cancer (NSCLC), melanoma and head and neck cancer whose tumors show initial resistance or initially respond to but subsequently develop resistance to immune checkpoint blockade therapy. The combination expansion component also includes a cohort of patients with triple negative breast cancer (TNBC) who have not been previously treated with immune checkpoint blockade therapy, a cohort of patients with mesothelioma, a cohort of patients with adrenocortical carcinoma and a cohort of patients with high baseline blood levels of MDSCs. IPI-549 is an investigational compound and its safety and efficacy has not been evaluated by the U.S. Food and Drug Administration or any other health authority. About Infinity Cautionary Note Regarding Forward-Looking Statements OPDIVO® is a registered trademark of Bristol-Myers Squibb. [i] Kaneda, M., Messer, K., Ralainirina, N., Li, H., et al. PI3K? is a molecular switch that controls immune suppression. Nature, 2016 Nov;539:437–442. [ii] De Henau, O., Rausch, M., Winkler, D., Campesato, L., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K? in myeloid cells. Nature, 2016 Nov;539:443-447. [iii] www.clinicaltrials.gov, NCT02637531. Contact: View original content:http://www.prnewswire.com/news-releases/infinity-announces-presentations-on-ipi-549-at-upcoming-american-society-of-clinical-oncology-annual-meeting-300644761.html SOURCE Infinity Pharmaceuticals, Inc. |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |